Mortality and prognostic Factors in COVID-19 Patients with Hematologic Malignancies: A Retrospective Cohort Study in two Syrian centers

Author:

Mohamad Baraah1,Martini Nafiza1ORCID,Hanna Majd2,Alhamid Naji1,Sulaiman Ameen1,bardan Hussam Al1

Affiliation:

1. Damascus University Faculty of Medicine

2. Stemosis for Scientific Research

Abstract

Abstract

Background Patients with hematologic malignancies (HM) have poor outcomes from coronavirus disease (COVID-19), but data are limited, especially from low-income regions. This study analyzed mortality rates, clinical outcomes, and prognostic factors associated with COVID-19 infection in HM patients in Syria. Methods This retrospective cohort study enrolled 150 HM patients aged 16–78 years with confirmed COVID-19 at two hospitals in Damascus during 2021–2022. Patients were diagnosed based on RT-PCR or clinical/radiological findings with Chest computed tomography (CT) scans being the primary diagnostic modality. Data on demographics, cancer type, symptoms, comorbidities, CT findings, and outcomes were collected through medical records. Results The median age was 52.68 (± 18.49) years, with 64% of patients’ ≥50 years old. Acute lymphoblastic leukemia (18%) and acute myeloid leukemia (16.7%) were the most common HM types. The overall mortality rate was 61.4%. Mortality was significantly associated with older age (p = 0.001), cancer type (100% for acute leukemias, p = 0.001), Presence of dyspnea, cough, or digestive symptoms (p = 0.001), severe CT lung infiltrates (p = 0.001), and Pre-existing medical conditions (p = 0.001). Nearly, 37.3% of patients required ICU admission. All patients with non-Hodgkin's lymphoma survived, while all acute leukemia patients died. Conclusion Advanced age, specific cancer types, symptomatic presentation, CT severity, and presence comorbidities were identified as prognostic factors for COVID-19 mortality in HM patients. These high-risk patients warrant vigilant screening and preventive measures. Additional research is urgently needed to guide protection and clinical management in this vulnerable population.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3